Document Detail

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
MedLine Citation:
PMID:  21557773     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND AIM: We investigated whether intrahepatic markers could predict response in chronic hepatitis B virus (HBV) patients treated with peg-interferon and adefovir for 48 weeks.
METHODS: Intrahepatic covalently closed circular DNA (cccDNA), total intrahepatic HBV DNA and the proportion of hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) positive hepatocytes in 16 hepatitis B e antigen (HBeAg) positive and 24 HBeAg negative patients were measured at baseline and at end of treatment.
RESULTS: Baseline intrahepatic markers were not associated with sustained virological response (SVR) defined as HBV DNA < 2000 IU/mL and persistent normal alanine aminotransferase levels at the end of follow-up (week 72). At end of treatment, intrahepatic cccDNA and total intrahepatic HBV DNA in HBeAg positive patients were significantly lower in patients with HBeAg seroconversion (P = 0.016 and P = 0.010) with positive predictive values (PPV) for SVR of 80% and 80%, respectively. In HBeAg negative patients, intrahepatic cccDNA and total intrahepatic HBV DNA had declined significantly at end of treatment (P = 0.035 and P = 0.041) and corresponding PPV for SVR was 73% and 82%. In HBeAg positive patients, median proportion of HBcAg positive hepatocytes declined significantly (P = 0.002) at end of treatment. In HBeAg negative patients, the proportion of HBsAg positive hepatocytes had declined significantly at end of treatment (P = 0.0009). Using HBsAg ≤ 7.5% as a limit, PPV for SVR in HBeAg negative patients was 83%.
CONCLUSIONS: At end of treatment in HBeAg positive patients, intrahepatic cccDNA and total intrahepatic HBV DNA were predictive for SVR. In HBeAg negative patients a proportion of < 7.5% HBsAg positive hepatocytes at end of treatment was a strong predictor for SVR.
Bart Takkenberg; Valeska Terpstra; Hans Zaaijer; Christine Weegink; Marcel Dijkgraaf; Peter Jansen; Marcel Beld; Hendrik Reesink
Related Documents :
9135533 - Colonic wall thickness measured by ultrasound: striking differences in patients with cy...
9790483 - Brain positron emission tomography (pet) in chronic fatigue syndrome: preliminary data.
3815173 - Abdominopelvic computerized tomography and open peritoneal lavage in patients with blun...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  26     ISSN:  1440-1746     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-28     Completed Date:  2012-01-23     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  1527-35     Citation Subset:  IM    
Copyright Information:
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
Departments of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenine / analogs & derivatives*,  therapeutic use
Antiviral Agents / therapeutic use*
Biological Markers / analysis
Chi-Square Distribution
DNA, Circular / analysis*
DNA, Viral / analysis*
Drug Therapy, Combination
Hepatitis B Core Antigens / analysis
Hepatitis B Surface Antigens / analysis
Hepatitis B e Antigens / analysis
Hepatitis B virus / drug effects*,  genetics,  immunology
Hepatitis B, Chronic / diagnosis,  drug therapy*,  virology
Interferon-alpha / therapeutic use*
Liver / drug effects*,  pathology,  virology
Middle Aged
Organophosphonates / therapeutic use*
Polyethylene Glycols / therapeutic use*
Polymerase Chain Reaction
Predictive Value of Tests
Recombinant Proteins / therapeutic use
Time Factors
Treatment Outcome
Viral Load
Reg. No./Substance:
0/Antiviral Agents; 0/Biological Markers; 0/DNA, Circular; 0/DNA, Viral; 0/Hepatitis B Core Antigens; 0/Hepatitis B Surface Antigens; 0/Hepatitis B e Antigens; 0/Interferon-alpha; 0/Organophosphonates; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 6GQP90I798/adefovir; 73-24-5/Adenine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased CD4(+) CD69(+) CD25(- ) T cells in patients with hepatocellular carcinoma are associated w...
Next Document:  Pregnancy and risk of acute myeloid leukaemia - a case-control study.